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Successful HIV-1 infection requires a number of specific stages leading to integration of the provirus. We previously suggested that members
of the VPAC neuroendocrine receptor family may play a role in HIV-1 infection. We now show that stimulation of the VPAC2 receptor with
specific agonists provides strong resistance to HIV-1 infection. Daily stimulation of VPAC2, but not VPAC1 or PAC1, resulted in up to 90%
inhibition of X4 or R5 productive infections in either cell lines or PBMCs. VPAC2 agonist stimulation had no effect on cell surface co-receptors,
the rate of apoptotic cells, or HIV-1 entry or reverse transcription of viral RNA. However, we provide evidence that VPAC2-specific agonists
inhibit HIV-1 infection through an inhibitory effect on the ability of the HIV-1 cDNA to integrate into the host DNA. These data reveal that
VPAC2 agonists are appropriate candidates for further study as possible treatments aimed at the amelioration of HIV/AIDS.
© 2007 Elsevier Inc. All rights reserved.Keywords: VPAC2 receptor; HIV/AIDS; VPAC2 agonists; Helodermin; HIV integrationIntroduction
It has long been appreciated that HIV-1 infection requires the
expression of both CD4 and a chemokine co-receptor for
infection of susceptible cells (Dalgleish et al., 1984; Alkhatib et
al., 1996; Feng et al., 1996). More recent studies have shown
that other receptors, such as DC-SIGN, may also play a role in
HIV pathogenesis (Turville et al., 2003), while other investi-
gators have begun to address in earnest the potential role of
other cell surface molecules such as glycosphingolipids in HIV
pathogenesis (Fantini et al., 2000; Puri et al., 2004; Lund et al.,
2006). Furthermore, we have previously reported that a
neuroendocrine receptor, VPAC1, may act to facilitate HIV-1
infection (Branch et al., 2002). Thus, the entire spectrum of host
factors important for HIV infection remains incomplete.⁎ Corresponding author. Canadian Blood Services/Toronto General Research
Institute, 67 College Street, Toronto, Ontario, Canada M5G 2M1. Fax: +1 416
974 9757.
E-mail address: don.branch@utoronto.ca (D.R. Branch).
0042-6822/$ - see front matter © 2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.12.012Several receptors have been described (Ulrich et al., 1998)
that interact with structurally-related regulatory neuroendocrine
peptides including vasoactive intestinal peptide (VIP), secretin,
and pituitary adenylate cyclase-activating polypeptide
(PACAP) (Ulrich et al., 1998; Harmar et al., 1998). These
neuroendocrine receptors belong to the class II (or group B)
subfamily of 7-transmembrane G-protein-coupled receptors
(Ulrich et al., 1998; Harmar et al., 1998). There are three
members of this receptor family: VPAC1 (Sreedharan et al.,
1993), VPAC2 (Svoboda et al., 1994) and PAC1 (Ulrich et al.,
1998; Harmar et al., 1998). One or more of these receptors can
be found in almost all human tissues including human immune
cells and brain cells, both targeted by HIV-1.
Investigators have previously alluded to a possible role of
neuroendocrine peptides in HIV infection (Pert et al., 1988).
Early reports claimed that antibodies present in HIV infected
individuals showed spectral and sequence homologies to VIP
and peptides derived from HIV-1 gp120 that bound these
antibodies (Veljkovic et al., 1992). Indeed, we have previously
shown that using specific antibodies to VIP can recognize and
Fig. 1. Helodermin inhibits productive HIV-1 infection of cells expressing
VPAC2. (A) Jurkat cells that express both VPAC1 and VPAC2 were treated with
5×10−5 M helodermin for 1 h prior to infection. Treated and untreated cells
were washed and then infected with HIV-1IIIB (moi, 0.1). Cells were washed and
cultured for 4 days. The level of infection was measured by p24gag production at
days 2 and 3, respectively. The results represent the mean pg/ml p24gag±SEM
from four separate cultures (*p=0.0001; **p=0.04). Similar results were
obtained in six additional independent experiments. (B) Expression of VPAC2
mRNA in transfected and wild type Hut78 cells by RT-PCR. (C) Hut78 cells,
untransfected or transfected with VPAC2 cDNA, were infected with HIV-1IIIB
and left untreated for 4 days. The level of productive infection was measured by
p24gag production. (D) Hut78 cells, untransfected or transfected with VPAC2
cDNA, were untreated or treated with 5×10−5 M helodermin for 1 h prior to
infection with HIV-1IIIB, then washed and cultured for 3 days. The results
represent the mean pg/ml p24gag±SEM from four separate cultures (*p=0.008).
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shown, in vitro, that VIP and other VPAC1 and VPAC2
agonists, but not VPAC2-specific agonists, can directly activate
HIV-1 transcription via the HIV-1 long terminal repeats (LTR)
(Gilles et al., 1998) and we have recently shown that HIV-1
interacts with VPAC1 on the cell surface to transduce a
facilitation signal for HIV-1 infection that can increase
productive infection; we speculated that this may be through
effects on integration/transcription (Branch et al., 2002).
Significant differences exist between VPAC1 and VPAC2,
both in structure and function (Nicole et al., 1998; Xia et al.,
1996; Tsutsumi et al., 2002; Bokaei et al., 2006). These two
receptors, although having similar extracellular and transmem-
brane domain structure, have very different cytoplasmic tails
with the potential for differential signaling. Indeed, there are
reports that indicate opposing functions of these two receptors
(Xia et al., 1996; Tsutsumi et al., 2002). Of significance is that
agonist stimulation of VPAC receptors, including agonists that
cross-react with VPAC1 and VPAC2, only activate LTR
transcription through VPAC1 stimulation (Gilles et al., 1998).
This possibility of differential signaling coupled with opposing
functions involving VPAC1 and VPAC2 led us to hypothesize
that, if VPAC1 stimulation results in facilitation of HIV-1
infection (Branch et al., 2002) and activation of LTR transcrip-
tion (Gilles et al., 1998), then stimulation of VPAC2may have an
opposing functional outcome and result in inhibition of HIV-1
infection. Therefore, the aim of this current study is to test this
hypothesis. Our results, presented herein, support this hypoth-
esis as we show that by using specific agonists to stimulate
VPAC2, we are able to significantly inhibit productive HIV-1
infection. Moreover, we show that this inhibitory effect is likely
mediated by a profound negative effect on the ability of the viral
cDNA to successfully integrate into the host genome.
Results
VPAC2 stimulation inhibits HIV-1 infection
To test the hypothesis of an inhibitory role of VPAC2 in HIV
infection, we initially used helodermin, a 35 amino acid peptide
originally isolated from the saliva of the Gila monster
(Helodermis suspectum) that preferentially stimulates VPAC2
(Robberecht et al., 1996). We found that a single helodermin-
pretreatment of Jurkat cells prior to HIV-1IIIB infection resulted
in a dose-dependent inhibition of productive infection (data not
shown). Complete inhibition of HIV-1 infection was achieved,
but this required relatively high concentrations of helodermin
(10−4 M), the IC50 was 10
−5 M. Furthermore, this inhibitory
effect of helodermin was transient. Thus, when using a single,
high-dose of helodermin, the inhibition of HIV-1 infection of
Jurkat cells was greatest on day 2 (73%, p=0.0001) when
compared to day 3 (42%, p=0.04) (Fig. 1A).
Hut78 cells expressing VPAC2 are resistant to HIV-1 infection
To ascertain whether the inhibitory activity of a single high-
dose pre-treatment with helodermin was mediated by VPAC2,we used Hut78 cells transfected with VPAC2. Hut78 are
infected with HIV-1 but do not express endogenous VPAC2
(Xia et al., 1996). Using a high expressing clone (Fig. 1B), we
first confirmed that the level of infection for either transfected or
untransfected Hut78 was equal when there was no helodermin
(Fig. 1C). We next showed resistance to infection of Hut78
transfected to over-express VPAC2 when pre-treated with
helodermin compared to helodermin-treated untransfected cells
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infection appears to be mediated through the VPAC2 receptor.
Daily treatment with low-dose VPAC2 agonists sustains
resistance to HIV-1 infection
To explore whether the transient nature of the inhibitory
effect of VPAC2 agonist stimulation can be overcome, we used
daily treatment with much lower concentrations of VPAC2
agonists. We now found that Jurkat cells treated daily withFig. 2. Daily treatment of Jurkat or PBMCs with VPAC2-specific agonists results in
infection with 5×10−5 M of each VPAC agonist and then washed. Cells were then inf
10−9 M of each VPAC agonist was added to the culture. Samples were withdrawn
determination of p24gag. (A) Effect of daily addition of helodermin. The results repre
(*p=0.03) and day 5 (**p=0.002). (B) Effect of daily addition of R3P55 peptide (VP
p24gag±SEM from four separate cultures assayed on day 4 (*p=0.06) and day 6 (*
secretin (VPAC1 agonist), PACAP (PAC1 agonist) or R0 25-1553 (VPAC2 agonist).
mean pg/ml p24gag±SEM from four separate cultures (*p=0.002). (D) Expression of
treatment with 10−9 M helodermin on infection with R5 (0.5 pg p24gag) virus of PB
assayed on day 5 (*p=0.024). (F) Effect of daily treatment of 10−9 M helodermin on
p24gag±SEM for four separate cultures assayed on day 5 (*p=0.017).10−9 M helodermin show ∼90% inhibition of HIV-1 infection
that is sustained over time post infection when compared to
untreated cells (p=0.002)(Fig. 2A). To confirm that inhibition
of HIV-1 infection is through VPAC2 receptor, additional high-
affinity selective agonists to VPAC2 and other VPAC receptors
were tested. We first tested R3P55 peptide and a control peptide
called PAC10 that has no activity for VPAC receptors (Tsutsumi
et al., 2002). Using daily treatment with 10−9 M of each
peptide, there was no inhibition of HIV-1 infection using
PAC10-treated Jurkat cells compared to untreated cells.inhibition of productive HIV-1 infection. Cells were pretreated for 1 h prior to
ected with HIV-1IIIB for 1 h, washed and cultured. Each day following infection,
at the indicated time points for measurement of productive HIV-1 infection by
sent the mean pg/ml p24gag±SEM from four separate cultures assayed on day 3
AC2 agonist) or PAC10 (control peptide). The results represent the mean pg/ml
*p=0.004). (C) Effect of daily addition of VIP (VPAC1 and VPAC2 agonist),
The level of infection was measured at day 7 of culture. The results represent the
VPAC2 mRNA in resting and activated PBMCs by RT-PCR. (E) Effect of daily
MCs. Results represent the mean pg/ml p24gag±SEM for four separate cultures
infection with X4 (moi, 0.3) virus of PBMCs. Results represent the mean pg/ml
41P.B. Bokaei et al. / Virology 362 (2007) 38–49However, significant inhibition (75%; p=0.004) of HIV-1
infection with R3P55 was observed; this inhibitory effect was
evident for at least 1 week post-infection (Fig. 2B). To further
show specificity of the inhibitory activity, the effect of agonists
specific for other members of the VPAC receptor family were
tested. VIP, which can engage both VPAC1 and VPAC2 (Usdin
et al., 1994), secretin which has a higher affinity for VPAC1
than VPAC2 (Gourlet et al., 1997a), PACAP1–38 which has
highest affinity for PAC1 (Ulrich et al., 1998; Arimura and
Shioda, 1995) and R0 25-1553, highly specific for VPAC2
(Gourlet et al., 1997b) were tested. Daily treatment with 10−9 M
of each of these peptides revealed significant inhibition of HIV-
1 infection (75%; p=0.002) only with R0 25-1553. No
inhibition was observed for cells that had been treated with
PACAP or secretin (Fig. 2C). Although there was slight
inhibition when VIP was used, this is likely because VIP
interacts with both VPAC1 and VPAC2 with similar affinity
(Ulrich et al., 1998; Svoboda et al., 1994; Gourlet et al., 1997a);
thus, these results may indicate that the facilitating effect of
VPAC1 (Branch et al., 2002) competes well with the inhibitory
effect of VPAC2 or, relates to the relative receptor density on
Jurkat cells. Taken together, these results indicate that the
inhibitory effect on HIV-1 infection is specifically mediated
through VPAC2. Furthermore, the inhibitory activity can be
sustained by using daily treatments with low concentrations of
VPAC2 agonists.
To study the effect of VPAC2 agonists on HIV-1 infection of
primary cells, additional experiments were performed using
human PBMCs treated with helodermin. It has been reported
that resting CD4+ cells express VPAC1 in high levels, while
activated CD4+ cells predominantly express VPAC2 receptors
(Lara-Marquez et al., 2001); confirmed using RT-PCR (Fig.
2D). Thus, activated CD4+ cells would be a good model for
examining the effect of VPAC2 agonists on primary cell HIV-1
infection. Activated PBMCs were pretreated with 5×10−5 M
helodermin, which was followed by daily treatments using
10−9 M helodermin. Fig. 2E shows the ability of helodermin to
inhibit infection with R5 (HIV-1Ba-L) (p=0.024). Inhibition of
the infection is significant up to 5 days in culture. Fig. 2F shows
VPAC2 agonists inhibit an X4 virus (HIV-1IIIB) (p=0.017).
These data indicate that the effect of VPAC2 stimulation is
active for inhibition of normal peripheral blood HIV infection
and is not strain specific.
VPAC2 agonists do not affect CD4 and co-receptor expression,
cell growth or HIV-1 entry and reverse transcription
After pre-treatment of Jurkat cells with 5×10−5 M helo-
dermin followed by daily treatment with 10−9 M for 2 days,
FACS analysis to evaluate the level of cell surface expression of
CD4 and CXCR4 showed no differences compared to untreated
control cells (Fig. 3A). We also evaluated the number of viable
and apoptotic cells and found no differences between untreated
and helodermin-treated cells (Figs. 3B and C). In addition, we
evaluated the level of receptor expression, apoptosis, and viable
cells after 5 days. There was no difference between untreated
and helodermin treated cells (data not shown).To further investigate the mechanism by which VPAC2
agonists inhibit productive HIV-1 infection, we began an
examination as to whether there is a block in one or more of the
early stages of the HIV-1 life cycle. We first determined whether
VPAC2 agonist stimulation results in inhibition of virus entry.
We found that treatment of Jurkat with 5×10−5 M helodermin
did not affect cellular entry when compared to untreated Jurkat
cells (Fig. 4A). This was also true for Jurkat cells treated with
the VPAC2-specific agonist R3P66 compared to Jurkat cells
treated with the control peptide, PAC6 (data not shown).
Furthermore, in order to investigate whether VPAC2 agonists
have any effect on middle and late stages of reverse
transcriptase (RT), we evaluated the level of gag and LTR/gag
regions of HIV-1 cDNA in a time-dependent manner. The levels
of HIV-1 cDNAwere similar for untreated and VPAC2 agonist-
treated cells (Fig. 4B). In addition, we used real-time PCR to
detect the level of LTR/gag, the late stage of RT activity, for
untreated and helodermin treated cells. Fig. 4C indicates that the
level of HIV-1 cDNA was equal for untreated and VPAC2
agonist-treated cells; indicating that VPAC2 agonists have no
effect on HIV-1 reverse transcriptase activity.
VPAC2 agonists inhibit reporter gene expression using
pseudoenvelope-typed HIV-1
To continue our examination as to where in the HIV life
cycle VPAC2 agonists exert their effect, we monitored the
effects of helodermin on infection using the pseudoenvelope-
typed viruses, VSV-G/NL4-3luc and JR-FL/NL4-3GFP. VSV-
G/NL4-3luc virus does not require CD4 or co-receptors for
infection and is replication deficient having a luciferase reporter
gene inserted into the viral nef gene (Connor et al., 1995). JR-
FL/NL4-3GFP carries a human R5 viral envelope and is also
replication deficient having a green fluorescent protein (GFP)
gene inserted into the viral nef gene. Thus, monitoring of
luciferase production or GFP fluorescence will allow us to
determine if the negative effect of VPAC2 agonists on
productive HIV-1 infection occur post reverse transcription of
the HIV-1 virus and at the transcriptional or integration stage.
Using both pseudoenvelope-typed viruses will also allow an
assessment of possible crosstalk required between viral
envelope-specific cell surfaces receptor signaling and the
VPAC2-stimulated signal for maximal inhibitory effect. We
found that helodermin could inhibit luciferase production from
Jurkat cells infected with the VSV-G/NL4-3luc virus (Fig. 5A).
Similarly, using PBMCs, we found that helodermin treatment
could inhibit the percent of cells expressing GFP following
infection with JR-FL/NL4-3GFP (Fig. 5B). The inhibitory
effect resulted in ∼60% and ∼90% inhibition of reporter gene
detection, respectively. This inhibition occurs after one cycle of
infection. Over time, this immediate effect may appear much
stronger. Although it appears that when using the R5
pseudoenvelope-typed virus compared to the VSV-G pseu-
doenvelope-typed virus that there is increased inhibition,
whether this is a result of crosstalk between signals sent
through VPAC2 and the cell surface receptors recognized by the
R5 envelope remains to be elucidated. Importantly, this
Fig. 3. Effect of daily administration of helodermin on CD4 and CXCR4 expression, apoptosis, and cell proliferation. Jurkat cells were pretreated with 5×10−5 M
helodermin for 1 h, washed and then treated daily with 10−9 M helodermin for 48 h. (A) Two-color FACS analysis was used to compare CD4 and CXCR4 expression in
helodermin-treated and untreated Jurkat cells. (B) FACS analysis for apoptosis, viable and dead cells was done with and without helodermin treatment after 48 h using
propidium iodide (PI) and binding of Annexin V-FITC. (C) Effect of helodermin on cell growth was determined by counting cells that excluded Trypan blue using a
hemocytometer. These results are representative of three independent experiments.
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HIV-1 infection by VPAC2 agonists likely occurs at either the
integration or transcription stage of the HIV-1 life cycle or at a
stage between the reverse transcription and integration stages.
VPAC2 agonists inhibit HIV-1 integration
To ascertain whether the inhibition of the production of
luciferase and GFP was a result of VPAC2 effects on
transcription/translation or on viral integration, we next
examined the effect of VPAC2 agonist treatment on the
integration of the HIV-1 cDNA into the host DNA. Jurkat
cells were pretreated with 5×10−5 M helodermin for 1 h,
washed and then infected with HIV-1IIIB. Infected cells were
then treated daily with 10−9 M helodermin (stimulates VPAC2)
or secretin (stimulates VPAC1) in parallel with untreated Jurkat
cells. Genomic DNA was extracted and subjected to nested
LTR-Alu PCR. Final products were cut with Hinf I to give a
specific predicted fragment size of 385 bp (Fig. 5C). Theamplified products were run on a 1.5% agarose gel and
subjected to Southern blotting with a radiolabelled HIV-1
specific probe. Fig. 5D reveals that cells that were treated with
helodermin, but not secretin, had profoundly less, sometimes
undetectable, levels of integrated HIV-1 cDNA.
Discussion
We present evidence showing that stimulation with specific
agonists of the neuroendocrine receptor, VPAC2, results in a
marked inhibition of productive HIV-1 infection. Moreover, our
studies reveal that the effect of VPAC2-specific agonists on
productive infection is to inhibit the cDNA integration of the
HIV-1 provirus into the host genome. Thus, we show a means to
inhibit HIV-1 integration that uses exogenous stimulation of a
host cellular receptor by a potential pharmacological agent.
Our in vitro experiments have revealed that three well
characterized stimulators of VPAC2, helodermin, RO 25-1553,
and the R3P series of VPAC2 agonists, all inhibit productive
Fig. 4. VPAC2 agonists have no effect on HIV-1 entry or reverse transcriptase
activity. For examination of the very early stage of viral entry (detection of LTR),
Jurkat (Jk) cells were untreated or treated for 1 h with 5×10−5 M helodermin or
0.4 μMAZTand then infected for 1 h with HIV-1IIIB (moi, 0.3) that had first been
treated with DNAse I. Cells were then washed and trypsinized to remove virions
attached to the cell surface, washed again and allowed to remain in culture for
30 min. Additional controls consisted of uninfected Jk cells and Jk cells infected
with heat-inactivated, killed, HIV-1IIIB virus. For the examination of later stages
of viral reverse transcription (RT), untreated Jk or Jk cells treated for 1 h with
5×10− 5 M helodermin were infected as above and cultured for 3 and 7 h for
detection of gag and LTR/gag, respectively. Then, cell lysates were prepared and
HIV-1 viral cDNA was detected by amplifying different regions of the HIV-1
genome in order to detect different stages of RT activity. Specific primers for
LTR, gag, and LTR/gag regions of HIV-1 were used (seeMaterials andmethods).
(A) For detecting entry and the very early stage of RT activity, the HIV-1 LTR
region was evaluated; Lane 1, DNA ladder; lane 2, −ve control (water); lane 3
(uninfected Jk); lane 4, Jk cells infected with heat-inactivated, killed, virus; lane
5, AZT-treated, infected Jk cells; lane 6, helodermin-treated infected Jk; lane 7,
untreated infected Jk cells. The 180 bp fragment represents viral cDNA. As a
control for RT-PCR, we used β-globin, represented by the 268 bp fragment (B)
For middle and late stages of RTactivity, gag and LTR/gag regions of viral cDNA
for untreated and VPAC2 agonist-treated cells were evaluated. The 268 bp
fragment represents the control comparison of the β-globin DNA level in
analyzed samples. The results are representative of at least two independent
experiments. (C) Real-time PCR was also performed for the LTR/gag region of
HIV-1 cDNA. The same samples that had been used for PCR were used for this
reaction. The threshold/cycle (Ct) values were determined for VPAC2 agonist-
treated and untreated cells and normalized to Ct values for β-globin. The result is
represented as the delta Ct, comparing the Ct of LTR/gag to the Ct for β-globin.
Samples were run in triplicates.
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that a single bolus high-dose (5×10−5 M) of the VPAC2
agonist, helodermin, could inhibit HIV-1 X4 infection of a
human T cell line. However, the inhibitory effect was transient,
with productive infection being delayed in onset but eventually
able to catch up to the untreated infection level. We surmised
that the requirement for high concentration and the transient
nature of the inhibition although, perhaps partly due to the
agonist having a short half-life in culture, was likely due to
desensitization of the VPAC2 receptor resulting in down-
regulation of the receptor as has been reported for other agonist
stimulators of 7-transmembrane G-protein-coupled receptors
(Hirsh et al., 2005; Langlet et al., 2004) Thus, we reasoned that
a physiological concentration of agonist using multiple
treatments would be more effective at maintaining a sustained
inhibitory activity over time. Indeed, using concentrations of
VPAC2 agonists that were within the affinity constant range of
VPAC2/ligand interaction (Gourlet et al., 1997a; Langlet et al.,
2004), we found this approach very effective to sustain the
inhibition of productive HIV-1 infection over time in culture.
Although we examined the inhibitory activity of VPAC2
agonists using 10−9 M of agonist throughout the treatment
regimen, we used 5×10−5 M agonist as the initial treatment
followed by 10−9 M daily treatments because this higher initial
treatment resulted in a more substantial sustained inhibition.
The reason for this is unclear but may involve independent
pathways that utilize high and low dose agonist as has been
previously described (Sausville et al., 2003) or due to an initial
requirement of a higher concentration to initiate the necessary
signaling pathway that can then be sustained at lower
concentrations. It is not unusual for clinical treatment regimens
to begin treatments using a higher dose of therapy followed by
lower maintenance doses (Vey et al., 2006; Sausville et al.,
2003).
Using Jurkat cells that express both VPAC1 and VPAC2
(Branch et al., 2002), we were able to inhibit the infection
through VPAC2-specific stimulation, even in the face of HIV-1
that we have previously shown can bind to VPAC1 and provide
a facilitation signal to enhance infection (Branch et al., 2002).
This result implies that the inhibitory signal sent through
VPAC2 is dominant over the facilitation signal sent through
VPAC1 when HIV-1 interacts with this receptor. Differences in
inhibitory effect could also be explained by the density of the
VPAC2 expression compared to that of VPAC1 on these cells.
In primary cell infections, we use cells that have first been
activated. This produces cells having maximum expression of
VPAC2 and minimal expression of VPAC1 (Lara-Marquez et
al., 2001; Bokaei et al., 2006) and overcomes any facilitation
effects of the virus through VPAC1.
Our results clearly show that the mechanism of inhibition of
productive HIV-1 infection is by a VPAC2-mediated blockade
in the ability of the HIV-1 cDNA to successfully integrate into
the host DNA. Furthermore, we show that this block occurs
after full reverse transcription to viral cDNA. Future studies will
examine VPAC2-mediated effects on the HIV-1 pre-integration
complex and focus on the association of the p17 matrix and
integrase proteins.
Fig. 5. VPAC2 agonists inhibit HIV-1 integration. (A) Jurkat cells were untreated or treated with 5×10−5 M helodermin for 1 h, washed, and then infected with 25 ng
VSV-G/NL4-3luc pseudoenvelope-typed HIV-1 virus. After 24 h, the cells were treated again with 10−9 M helodermin for another 24 h. Then, cells were lysed and
luciferase activity measured using a luminometer. Results represent the mean relative fluorescence units (RFU)±SD of triplicate cultures (*p=0.017). (B) Human
primary PBMCs were activated with PHA (10 μg/ml) for 48 h. Activated cells were either untreated or treated with 5×10−5 M helodermin for 1 h, washed, and then
infected with 400 ng JR-FL/NL4-3GFP pseudoenvelope-typed HIV-1 virus. After 24 h, the treated cells were again treated with helodermin (10−9 M) for another 24 h.
Then, cells were tested for GFP reporter gene expression by FACS analysis, using untreated cells as representing 100% GFP-expressing cells to determine the percent
of GFP-expressing cells in the helodermin-treated sample. To determine the effect of helodermin on integration of the viral cDNA, Jurkat cells were untreated or treated
with 5×10−5 M helodermin or secretin for 1 h, washed, and then infected with HIV-1IIIB. Cells were then treated with 10
−9 M helodermin or secretin for 2 days and
then processed for determination of integrated HIV-1 cDNA. (C) Schematic representation of the nested PCR strategy to determine the 385 bp fragment that represents
integrated HIV-1 DNA. F1 and F2 are the first and second round PCR forward primers that recognize the 3′LTR region of HIV-1 while Alu-R represents the common
reverse primer that is specific for human Alu-repeat sequences within the human genome. Hinf I indicates the approximate cut site to produce the 385 bp fragment to be
confirmed by Southern blotting. (D) The amplified products were run on a 1.5% agarose gel and subjected to Southern blotting with a radiolabelled HIV-specific probe.
A separate HIV-LTR fragment was subjected to separate PCR using primers corresponding to the HIV-1 LTR region to give a 540 bp fragment that was used as a
Southern blot control. A 268 bp fragment represents the control comparison of β-globin DNA level in analysed samples. The result is representative of four
independent experiments.
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treatment of diabetes (Tsutsumi et al., 2002; Yung et al.,
2003) and perhaps will be shown useful in future therapies for
cancer (Schulz et al., 2004). Helodermin, derived from the Gila
monster lizard, has no human homologs (Pohl and Wank, 1998)
and has never been proposed for use in humans; but, our results
suggest that a possible use for this peptide could be in the
treatment of HIV/AIDS. Another Gila monster-derived peptide,
exendin-4, is currently receiving attention as a new therapy for
diabetes (Dupre, 2005) and Alzheimer's disease (Perry and
Greig, 2004). Thus, it is not inconceivable that helodermin or a
related peptide may show efficacy in HIV therapy. Recently, anewly synthesized VPAC2 agonist has been described having
even higher specificity and affinity for VPAC2 (Langer et al.,
2004). Whether this newly reported peptide will show increased
efficacy for prevention of productive HIV-1 infection remains to
be determined.
It is interesting that we have now found VPAC2 stimulation
to provide an inhibitory effect on HIV-1 infection. Previously,
we found that stimulation of VPAC1 was able to facilitate HIV-
1 infection and that the virus itself was able to interact with the
VPAC1 receptor to initiate the facilitation signal (Branch et al.,
2002). In that work, we provided evidence that the mechanism
of facilitation was most likely through an increased ability for
45P.B. Bokaei et al. / Virology 362 (2007) 38–49the viral cDNA to integrate into the host genome. Now, we show
that stimulation of VPAC2 inhibits HIV-1 infection by inhibiting
viral cDNA integration. Thus, our findings represent another
example of VPAC1 and VPAC2 having opposing functions.
In conclusion, we have further defined a potential role for
VPAC neuroendocrine receptors in HIV infection. We have
discovered that stimulation of the VPAC2 neuroendocrine
receptor results in a strong negative effect on productive HIV-1
infection through its ability to greatly impede HIV-1 cDNA
integration into the host DNA and that this effect is likely
mediated through a specific signal being transduced after
ligand/receptor interaction. Our discovery suggests that further
studies may determine that VPAC2 agonists provide a novel and
potentially potent therapy for HIV/AIDS that could be
developed for future utility as a new drug-based treatment in
the global fight against this terrible disease.
Materials and methods
Cells and growth assay
Sup-T1, Hut78, Jurkat E6.1 and 293T cells were purchased
from American Type Culture Collection and maintained in
complete medium (RPMI-1640/10% FBS; Sigma-Aldrich).
Normal whole blood was obtained from volunteers after informed
consent and peripheral blood mononuclear cells (PBMCs) were
isolated using density gradients. Cell growth was determined by
plating 107 cells into T25 flasks in complete medium and aliquots
withdrawn over time and viable cells enumerated in the presence
of Trypan blue dye using a hemocytometer.
VPAC1, VPAC2, and PAC1 receptor agonists
VIP, secretin, PACAP1–38 and helodermin were purchased
from American Peptide Company. RO 25–1553 was a gift from
Dr. Patrick Robberecht (University of Brussels). R3P55,
R3P66/BAY 55–9837, PAC10, and PAC6 peptides were
provided by Dr. Clark Pan (Bayer Corporation). VIP can
engage both VPAC1 and VPAC2 (Ulrich et al., 1998), secretin
has a much greater affinity for VPAC1 than VPAC2 (Gourlet et
al., 1997a), PACAP1–38 has a high affinity for PAC1 (Arimura
and Shioda, 1995), and helodermin (Robberecht et al., 1996),
R0 25–1553 (Gourlet et al., 1997b), R3P66/BAY 55–9837
(Tsutsumi et al., 2002), and R3P55 (Yung et al., 2003) are
specific for VPAC2.
Viruses and virus infection
HIV-1IIIB (X4) and HIV-1Ba-L (R5) were from the NIH AIDS
Research and Reference Reagent Program (Rockville) and used
at a multiplicity of infection (moi) of 0.1 infectious virions (i.v.)/
cell for X4 strain in cell lines and 0.3 moi for human PBMCs;
for R5 viruses, 0.5 pg total p24gag/0.5×106 cells was used. T
lymphocytes and monocytes were infected with X4 or R5 after
activation of PBMCs as previously described (Lund et al.,
2006). Initially, cell lines and activated primary cells were either
untreated or pretreated once with 5×10−5 M agonist peptidesfor 1 h, washed, infected for 1 h with HIV-1IIIB or HIV-1Ba-L,
washed again, and then cultured and monitored for viral
infection. In later experiments, cells were pretreated and
infected as previously stated but then, each day after infection;
an aliquot of culture supernatant was removed for testing and
replaced with an equal aliquot of medium containing peptides to
give a final concentration of 10−9 M. HIV-1 infection was
monitored by measurement of p24gag protein using ELISA
(Beckman/Coulter) (Lund et al., 2006; Branch et al., 2002).
Cloning VPAC2 cDNA
VPAC2 mRNA was isolated from Sup-T1 cells by using
QuikPrep Micro mRNA Purification Kit (Amersham Pharmacia
Biotech Inc.) and cDNA made using the First-Strand cDNA
Synthesis Kit (Amersham Pharmacia Biotech Inc.). PCR was
performed in a Perkin-Elmer Gene Amp PCR 9700 thermocycler
using Olerup SSP PCRMasterMix with 1 unit of Taq polymerase
(Genovison Inc). VPAC2 oligonucleotide primers were based on
Genbank database; accession no. L36566: sense; 1F (5′-
CACGCTGAGCTCGGGATGCGGA-3′) and antisense; 1R (5′-
CTAGATGACCGAGGTCTCCGTTTG-3′). DNA fragments
obtained by RT-PCR were directly cloned using the TA Cloning
System (Invitrogen/Gibco Canada Inc). A full length VPAC2
sequence from TA clones was confirmed by the dideoxy method
using reagents from Amersham Canada with the T7 and M13
primers.
Stable expression of VPAC2 in Hut78 cells
The cDNA encoding the full-length wild-type human
VPAC2 was inserted into the mammalian expression vector
pcDNA3.1 (Invitrogen). Transfection of Hut78 cells was carried
out as previously described for VPAC1 (Branch et al., 2002).
Stable clones expressing high levels of VPAC2 mRNA were
selected using limiting dilution. VPAC2 protein expression was
confirmed using immunoprecipitation with anti-Xpress tag of
35S-biosynthetically labelled VPAC2 as previously described
(Bokaei et al., 2006)(data not shown).
VPAC2 mRNA expression using RT-PCR
VPAC2 mRNA primers were: Forward primer, 5′-GTACTG-
CATCATGGCCAACT-3′; Reverse primer, 5′-CTAAGTA-
GAGCCTGGCCGC-3′. mRNAwas isolated using Quick Prep
Micro mRNA purification kit (Amersham Pharmacia Biotech
Inc) from approximately 2×106 cells; 1 μg of mRNA was
reverse transcribed to make cDNA using First Strand cDNA
Synthesis kit (Amersham Pharmacia Biotech Inc). A plasmid
containing a full-length VPAC2 insert was used as a positive
control. PCR products were separated by electrophoresis
through a 1.5% agarose gel and visualized by ethidium bromide.
Flow cytometry analysis
Two-color fluorescent antibody cell sorting (FACS) analysis
of CD4 and CXCR4 expression was accomplished as described
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Briefly, 1×106 cells were incubated with 10 μl mouse anti-
CXCR4 (12G5; NIH AIDS Research and Reference Reagent
Program) followed by 2 μL fluoresceine isothiocyanate (FITC)-
conjugated goat anti-mouse immunoglobulin (Biosource,
Camarillo, California, USA) and then with 10 μL phycoery-
thrin-labeled mouse anti-human CD4 (Serotec, Raleigh, North
Carolina, USA). FACS was performed using two-color analysis
on a flow-rate-calibrated (using BD CaliBRITE beads (Becton
Dickinson)) FACSCalibur E4795 flow cytometer (Becton
Dickinson, San Jose, CA, USA), and Cell Quest software for
data analyses (Becton Dickinson).
Viral entry and reverse transcriptase kinetic activity
Detection of viral entry and intracellular HIV-1 cDNA
following initiation of reverse transcriptase (RT) activation in
infected cells were assessed by DNA-PCR using primers
specific for the long terminal repeat (LTR), gag, and LTR/gag
regions of HIV-1 as previously described (Taddeo et al., 1993;
Baiocchi et al., 1997; Zack et al., 1990) with modification.
HIV-1IIIB was first treated for 30 min at 37 °C with DNAse I
(Boehringer) to degrade any possible viral DNA contamina-
tion. In order to detect viral entry, initially, Jurkat cells were
infected with the DNAse-treated HIV-1 for 1 h (moi, 0.3),
washed, and the cells trypsinized to remove any virions
attached to the cell surface. Additional controls for DNA
contamination included cells treated with 3′-azido-3′-deox-
ythymidine (AZT)(Mercure et al., 1994) during the infection
and Jurkat cells infected with heat-inactivated virus (65 °C for
3 h)(Taddeo et al., 1993). Subsequent studies of later stages of
viral reverse transcription (gag and LTR/gag) (Baiocchi et al.,
1997) were done using only virus that had been pretreated
with DNAse I followed by trypsin treatment of the cells. These
procedures for later stages of reverse transcriptase activity
were evaluated after infection for 1 h, and then cells were
washed and recultured in media for 3 and 7 h, respectively, in
order to detect gag and LTR/gag regions. After washing, total
cellular DNA was isolated by a quick lysis method using
PUREGENE DNA purification kit (Gentra Systems) and
different regions of HIV-1 cDNA were amplified by using
PCR with specific primers. Briefly, DNA was denatured at
95 °C for 4 min, and amplified by 35 cycles at 94 °C for
1 min, 58 °C for 1 min, 72 °C for 1 min, and a final extension
step of 7 min at 72 °C. The primers for amplification were: LTR:
forward, 5′-GCTGGGGACTTTCCAGGGAG-3′ and reverse,
5′-AGGCAAGCTTTATTGAGGCTTAAGC-3′; gag: forward,
5′-GCGCGCACAGCAAGAGGCGA-3′ and reverse, 5′-
GACGCTCTCGCACCCATCTC-3′; LTR/gag: forward: 5′-
GGCTAACTAGGGAACCCACG-3′ and reverse: 5′-CCTG-
CGTCGAGAGAGCTCCTCTGG-3′. Amplified products were
run on a 1.8% agarose gel and visualized by ethidium bromide.
Cell lysates were also concomitantly amplified using primers
specific for human β-globin as DNA control comparison. The
primers for β-globin gene were: forward, 5′-CAACTTCATC-
CACGTTCACC-3′ and reverse, 5′-GAAGAGCCAAGGA-
CAGGTAC-3′.Quantitative HIV-1 DNA analyses
The level of HIV-1 cDNA LTR/gag was measured by
quantitative real-time PCR as previously described (Victoria et
al., 2003; Bouchonnet et al., 2005; Vitone et al., 2005) with
modification. The same samples and specific primers were
used for evaluation of LTR/gag as described above. In brief,
reaction components were obtained from the LightCycler®
FastStart DNA Master SYBR Green PLUS I Kit (Roche,
Germany). Amplification, data acquisition and analysis were
carried out by the LightCycler® instrument (Roche, Germany).
The following reaction conditions were used: pre-incubation at
95 °C for 10 min, followed by 45 amplification cycles of
denaturation at 95 °C for 10 s, annealing at 60 °C (LTR/gag)
and 58 °C (β-globin) for 5 s, extension at 72 °C for 10 s,
melting curve analysis 65 °C for 15 s and a continues acqui-
sition mode of 95 °C with a temperature transition rate of 0.1
°C/s. The real-time PCR was performed in a final volume of
20 μl containing 1× Master SYBR green PLUS I buffer, 25 μM
forward and reverse primers , and 2 μl of template DNA
(100 ng/μl) plus no template as a control. The Light Cycler
instrument, determines the threshold cycles (Ct), which is
directly proportional to the log10 of the copy number of the
input templates (Vitone et al., 2005; Kurmayer and Kutzen-
berger, 2003). An equal amount of DNA in untreated and
VPAC2 agonist-treated samples was determined by spectro-
photometry (Gibellini et al., 2004) and samples were run in
triplicate. Results generated in Ct values were normalized to
β-globin Ct levels and the deltaCt value determined.
Pseudoenvelope-typed HIV-1 viruses
To generate an amphotropic or R5 enveloped HIV-1-
luciferase- or -GFP-containing recombinant virion, respec-
tively, 293T cells were used and co-transfected with plasmids
containing either an envelope gene or the HIV-1 genome
lacking env but containing a luciferase or GFP gene as
previously described (Connor et al., 1995; Branch et al., 2002;
Serafini et al., 2004; Chang et al., 1999). In brief, 15 μg of
plasmid HIV-1 NL4-3luc or HIV-1 NL4-3GFP (a kind gift
from Dr. Veneet KewalRamani, New York Medical Uni-
versity, NY), lacking the env gene and in which the firefly
luciferase (luc) or the green fluorescence protein (GFP) gene
is inserted into the viral nef gene (Connor et al., 1995), and
10 μg of a plasmid containing the amphotropic envelope of
the vesicular stomatitis virus (VSV-G env; a generous gift
from Dr. Michel Tremblay, Quebec City, PQ) or a plasmid
containing the human R5 envelope JR-FL (a gift from Vineet
KewalRamani, New York Medical University, NY), were
mixed with 875 μl of 0.25 M CaPO4 and then added dropwise
to 875 μl bubbling 2× BBS (0.28 M NaCl, 0.05 M BES,
1.5 mM Na2HPO4, pH 6.95). The mixture was then incubated
at room temperature for 15 min and the solution was gently
added to 2.5–3×106 293T cells plated into 10 cm Petri dishes
the day before transfection. Five hours post-transfection, cells
were washed with PBS and incubated for 72 h in fresh
DMEM medium with 10% FBS. The supernatant was
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through a 0.45 μm filter and pelleted by ultracentrifugation
over 20% sucrose for 1 h at 33,000×g. The virus-containing
pellet was resuspended in TNE buffer (20 mM Tris, pH 7.5,
1 mM EDTA, 100 mM NaCl), aliquoted and stored at
−80 °C. Virion content was determined by p24gag ELISA.
For infection using VSV-G/NL4-3luc, Jurkat cells were
untreated or treated with 5×10−5 M helodermin for 1 h,
washed, and then infected with the purified VSV-G/NL4-3luc
pseudoenvelope-typed virus, 25 ng per sample, in RPMI
medium (without phenol red) containing 10−9 M helodermin.
After 24 h, the cells were again treated with 10−9 M
helodermin and cultured for an additional 24 h. The cells
were then lysed using the cell culture lysis reagent (CCLR,
Promega Corporation, Madison, WI) as per the manufac-
turer's directions. 100 μl of luciferase assay substrate
(Promega Corporation) was added to 20 μl of cell lysate
and the luciferase activity immediately measured using a
luminometer (Luminoskan Ascent, Thermo Electtron Cor-
poration, Vantaa, Finland). For infection studies using JR-FL/
NL4-3GFP, PBMCs were activated with PHA for 48 h and
106 untreated or cells treated with 5×10−5 M helodermin for
1 h were infected with 400 ng per sample of the
pseudoenvelope-typed virus. After 48 h, the cells were
washed with PBS (×4) and the level of GFP activity
measured by FACS (Coulter-EPICS XL, Mississauga, Ontario
Canada). The percentage of GFP-expressing cells measured
in the infected but non-helodermin-treated cell population
was considered 100%. The number of GFP-expressing cells
in the helodermin-treated cell population was calculated as a
percentage of the total number of GFP-expressing cells in the
infected but untreated cell population.
HIV-1 cDNA integration
A modification of a previously reported (Daniel et al., 2003)
nested LTR/Alu-PCR strategy was used to specifically detect
integrated viral cDNA but not unintegrated forms. Briefly,
5×105 Jurkat cells per well in 12-well plates were left untreated
or were pretreated for 1 h with 5×10− 5 M of the agonist
peptides. Cells were washed, infected with HIV-1IIIB (moi, 0.1)
for 1 h, washed again and then cultured. Cultures were treated
daily with agonist peptides at a concentration of 10−9 M. At day
2 post-infection, cells were washed with PBS, lysed with 200 μl
of lysis buffer containing 0.4 mg proteinase K and total genomic
DNA collected in 50 μl of TE buffer (pH 8.3) with DNeasy
Tissue Kit (Qiagen). The nested-PCR reactions contained 1×
Olerup SSP PCR Master Mix with 1 unit of Taq polymerase
(Genovison), 0.25 mM forward and reverse primers. 2 μl and
4 μl of DNA, in, respectively, 10 μl and 20 μl total volumes, was
used for first- and second-round PCR, respectively, plus a no-
template control. DNA concentration of samples was normal-
ized by U.V absorbance and 400 ng DNAwas used for the first
round PCR. DNA was denatured at 94 °C for 4 min, then 35
cycles of 95 °C for 1 min, 56 °C for 1 min and 72 °C for 1 min;
and a final extension step of 7 min at 72 °C. The sense and
antisense primer pairs used were specific for the amplification ofthe HIV-1 LTR region and human Alu sequences, respectively.
The primers used for the first round PCRwere designed based on
the published sequence in the Genebank database (accession no.
NC001802) and were: Forward, LTRF1 (5′-GGGACTG-
GAAGGGCTAATTC-3′); reverse, AluR (5′-TGCTGGGAT-
TACAGGCGTGAG-3′). Products which were amplified in the
first round of the PCR were subjected to a second round of
amplification using: Forward, LTR F2 (5′- GAGAGCTG-
CATCCGGAGTAC-3′) and reverse, AluR. LTR-Alu products
generated from the second round of the nested-PCR were
extracted with QIA quick PCR Purification Kit (Qiagen) and
digested with the restriction endonuclease Hinf I (New England
Biolabs) which recognizes a unique site in HIV-1 LTR region to
yield a single internal integrated HIV DNA fragment from weak
smear forms. 10 μl of the cut DNAwith 2 μl loading buffer was
run on a 1.5% agarose gel. A control for Southern blotting was
2 μl of an HIV-LTR cDNA which had been subjected to PCR
using forward, LTR-F1, and reverse, LTR-R 5′- AGG-
CAAGCTTTATTGAGGCTTAAGC-3′ corresponding to HIV-
1 LTR region. After electrophoresis, the DNAwas transferred to
a nylon membrane (Hybond N+, Reche Diagnostic Co), fixed
and cross-linked. The membrane was prehybridized with
hybridization buffer at 42 °C for 1 h, followed by hybridizing
for 24 h at 42 °C with a HIV-1 LTR-specific radioactive (32P)
probe which was generated by random priming labelling
(Invitrogen/Gibco). The membrane was washed with hybridiza-
tion washing buffer and then exposed to X-ray film (Hyperfilm
MP). A single product of 385 bp indicated integrated viral cDNA
while a control HIV cDNA product of 540 bp indicated that the
radioactive probe and hybridization protocol is working.
Although this approach relies on a specific distance between
the LTR-Alu sequences, we have shown that this approach
works in Jurkat cells and has a sensitivity of 1000 infected Jurkat
cells. Cell lysates were also concomitantly amplified using
primers specific for human β-globin as DNA control
comparison.
Statistics
A paired Student's t-test was used for analysis of
significance. A p value<0.05 was considered significant.
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